328-OR: Hypoglycemia Associated with Physical Activity in Automated Insulin Delivery Users—Frequency and Prevention Strategies

Introduction 20 (15-25) g of carbohydrates), PA mode (18.8%), meal bolus reduction (15.6%), snacking during/after (11.2%; 24 (15-35) g of carbohydrates), pump disconnection (4.6%), and other strategies (16.5%; e.g. PA session suspended, or basal insulin reduced/suspended). Reported strategies per session were 29.6% for no strategy, 34.6% for one and 35.8% for 1. HE occurred 5 times during PA (1.1%), 28 (6.4%) 1-h post PA and 61 (14.0%) 4-h post-PA. PA intensity and duration are associated with HE during PA (p = 0.006 and p = 0.001, respectively). Insulin on board at PA start was not associated with HE, but last meal insulin bolus (before PA) was associated to 1-h post-PA HE (p = 0.018). Participants (n = 7) using an open-source AID had significantly less hypoglycemia 4-h post-PA (6.6 vs. 15.4% of sessions, p = 0.021). Conclusion: Carbohydrate intake is the most common prevention strategy. Incidence of hypoglycemia during PA is low but tends to increase after PA. Open-source AID may reduce post-PA hypoglycemia. Disclosure V. Boudreau: None. J.E. Yardley: Speaker's Bureau; Dexcom, Inc. Research Support; LifeScan Diabetes Institute. C.L. Russon: None. T. Chahal: None. R. St-Amand: None. R.P.R. Rabasa-Lhoret: Other Relationship; Abbott, AstraZeneca, Bayer Inc., Boehringer-Ingelheim, Dexcom, Inc. Research Support; Diabetes Canada. Other Relationship; Eli Lilly and Company. Research Support; Cystic Fibrosis Canada, Canadian Institutes of Health Research, FFRD - Fondation Francophone pour la Recherche du Diabète. Other Relationship; Janssen Pharmaceuticals, Inc. Research Support; Juvenile Diabetes Research Foundation (JDRF). Other Relationship; Novo Nordisk, GlaxoSmithKline plc. Consultant; HLS Therapeutics Inc., Insulet Corporation. Speaker's Bureau; CPD Networks. Other Relationship; Medtronic. Consultant; Pfizer Inc. Speaker's Bureau; Tandem Diabetes Care, Inc. Other Relationship; Sanofi. Speaker's Bureau; Vertex Pharmaceuticals Incorporated. Research Support; SFD - Société Francophone du Diabète. J. Molveau: None. Funding Diabetes Canada (OG-3-21-5586-RR)